Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688513's 5-Year Yield-on-Cost % is ranked worse than 64% of 150
companies
in the Biotechnology industry
Industry Median: 1.625
vs SHSE:688513: 1.08
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Chengdu Easton Biopharmaceuticals Co 5-Year Yield-on-Cost % Related Terms
SHSE:688513 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's 5-Year Yield-on-Cost % falls into.
Chengdu Easton Biopharmaceuticals Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a 5-Year Yield-on-Cost % of 1.08 as of Aug. 27, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is near median its historical median of 1.03. Over the past decade, Chengdu Easton Biopharmaceuticals Co's 5-Year Yield-on-Cost % has ranged from 0.54 to 1.99. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #96 out of 150 companies in the Biotechnology industry, placing it in the top 64%.
Is Chengdu Easton Biopharmaceuticals Co's 5-Year Yield-on-Cost % too high?
Chengdu Easton Biopharmaceuticals Co's current 5-Year Yield-on-Cost % of 1.08 is near median its 10-year median of 1.03. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 1.99. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.63. Chengdu Easton Biopharmaceuticals Co's value of 1.08 is 33.5% below this industry median. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #96 out of 150 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #96 out of 150 companies for 5-Year Yield-on-Cost %. This places Chengdu Easton Biopharmaceuticals Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.63. Chengdu Easton Biopharmaceuticals Co's value of 1.08 is 33.5% below this benchmark. Historically, Chengdu Easton Biopharmaceuticals Co's own 5-Year Yield-on-Cost % has ranged from 0.54 to 1.99 over the past decade. While the company's 10-year median is 1.03 vs. the industry median of 1.63, Chengdu Easton Biopharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.63, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Easton Biopharmaceuticals Co's current 5-Year Yield-on-Cost % of 1.08 is 33.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Easton Biopharmaceuticals Co's current 5-Year Yield-on-Cost % is 1.08, which is near median its own 10-year median of 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Fairly Valued. The stock's GF Value™ is ¥46.60, compared to a current price of ¥44.30 — trading 4.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.08, which is near median its 10-year median of 1.03 and 33.5% below the Biotechnology industry median of 1.63. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current 5-Year Yield-on-Cost % is 1.08 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥44.30 is trading 4.9% below its estimated GF Value™ of ¥46.60.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:688513:
5-Year Yield-on-Cost %: 1.08 (near median its 10-year median of 1.03)
GF Value™: ¥46.60 vs. price of ¥44.30 (4.9% below fair value)
Industry Position: 33.5% below the Biotechnology median (#96 of 150)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
94GF Score
Get the complete analysis for SHSE:688513
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
